SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-014793
Filing Date
2022-03-24
Accepted
2022-03-24 14:19:11
Documents
14
Period of Report
2022-03-24
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea157362-8k_immucell.htm   iXBRL 8-K 29255
2 ALLONGE TO AND AMENDMENT OF TERM NOTE, DATED MARCH 23, 2022, BETWEEN THE COMPANY ea157362ex99-1_immucell.htm EX-99.1 10845
3 MORTGAGE MODIFICATION AGREEMENT, DATED MARCH 23, 2022, BETWEEN THE COMPANY AND G ea157362ex99-2_immucell.htm EX-99.2 12946
  Complete submission text file 0001213900-22-014793.txt   231125

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE iccc-20220324.xsd EX-101.SCH 3033
5 XBRL LABEL FILE iccc-20220324_lab.xml EX-101.LAB 34476
6 XBRL PRESENTATION FILE iccc-20220324_pre.xml EX-101.PRE 22595
8 EXTRACTED XBRL INSTANCE DOCUMENT ea157362-8k_immucell_htm.xml XML 3484
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

IRS No.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12934 | Film No.: 22766035
SIC: 2835 In Vitro & In Vivo Diagnostic Substances